- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02817022
Developmentally Supportive Care on Neurobehavioral Outcome of Preterm Very Low Birth Weight Neonates (DSC)
Evaluation of the Effect of Application of Developmentally Supportive Care on Neurobehavioral Outcome of Preterm Very Low Birth Weight Neonates
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care (DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B. Both the groups will receive appropriate management for their morbidities as per existing NICU protocols. Both the groups will be followed up till 37 weeks of gestation where in their neurobehavioral assessment will be performed using Neurobehavioural assessment of preterm infants score.
In both the groups all the baseline data regarding antenatal factors will be recorded in a predesigned proforma such as age, gravid, Gestational age, Chorioamnionitis, Prenatal steroids, Multiple pregnancy, maternal comorbidities (preeclampsia, gestational diabetes mellitus), mode of delivery etc.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Delhi, India
- Recruiting
- Lady Hardinge Medical College,New Delhi
-
Contact:
- Vikram Datta, MD
- Phone Number: 919350801230
- Email: vikramdatta71@yahoo.com
-
Principal Investigator:
- Vikram Datta, MD
-
-
Delhi
-
New Delhi, Delhi, India, 110001
- Recruiting
- Lady Hardinge Medical College
-
Contact:
- Vikram Datta, MD,DNB
- Phone Number: +919899114104
- Email: drvikramdatta@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All stable preterm very low birth weight babies not on invasive mechanical ventilation
- Hemodynamically stable
- Parental consent
Exclusion Criteria:
- Babies with major congenital anomalies
- Asphyxia (Apgar score <3 at 5mins).
- Acute bilirubin encephalopathy
- Hypoglycemia at enrollment
- Clinical Chorioamnionitis(fever > 100.4 ◦ f , uterine fundal tenderness, maternal tachycardia (>100/min), fetal tachycardia (>160/min) and purulent or foul amniotic fluid )
- History of birth trauma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: developmentally supportive care
enrolled neonates will be provided routine supportive care as per existing NICU protocols.
This will be carried out in the initial 6 months (0-180 days) of study commencement.
This group will serve as control group (group A).
During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC).
DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment.
This group will be designated as group B
|
DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurobehavioral outcome Of the Preterm Very low birth weight babies
Time Frame: 18 months
|
Neurobehavioural outcome will be measured by NAPI at 37 weeks of corrected gestational age.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to achieve full feeds @150ml/kg
Time Frame: 18 months
|
Time to achieve full feed @150 ml/kg/day will be measured in days.
|
18 months
|
|
Length of hospital stay
Time Frame: 18 months
|
will be measured in days
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of apneic episodes during hospital stay
Time Frame: 18 months
|
will be measured as per standard definition of neonatal apnea and expressed as numbers.
|
18 months
|
|
IVH Grade 2 or more
Time Frame: 18 months
|
will be measured using bedside cranial sonogram and classified using Volpe's classification.
|
18 months
|
|
BPD
Time Frame: 18 months
|
Presence or absence will be noted and mentioned as yes or no.
|
18 months
|
|
NEC Stage 2 or more
Time Frame: 18 months
|
Will be staged using Bells staging .
|
18 months
|
|
ROP (any stage)
Time Frame: 18 months
|
Will be graded using standard classification .
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Developmental supportive care
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Very Low Birth Weight Baby
-
Chawarwan Saleem AbdullahHawler Medical UniversityActive, not recruitingVery Low Birth Weight Baby | Low Birth Weight BabyIraq
-
Mehmet YektaCompleted
-
Columbia UniversityNational Institute of Environmental Health Sciences (NIEHS); Thrasher Research... and other collaboratorsCompletedPneumonia | Very Low Birth Weight BabyUnited States, Ghana
-
RESnTEC, Institute of ResearchCompleted
-
Gadjah Mada UniversityCompletedPreterm | Very Low Birth Weight Baby | Trophic FeedingIndonesia
-
Sir Takhtasinhji General HospitalCompletedNeonatal SEPSIS | Very Low Birth Weight BabyIndia
-
University of ManitobaProlacta Bioscience; Children's Hospital Foundation; Manitoba Developmental Origins...CompletedHuman-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature InfantsPremature Birth | Microbial Colonization | Oxidative Stress | Very Low Birth Weight BabyCanada
-
Aga Khan UniversitySave the Children; Pakistan Ministry of HealthCompletedNeonatal Sepsis | Birth Asphyxia | Very Low Birth Weight BabyPakistan
-
The Hospital for Sick ChildrenActive, not recruitingVery Low Birth Weight InfantCanada
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkCompletedVery Low Birth Weight InfantsUnited States
Clinical Trials on developmentally supportive care
-
Memorial Sloan Kettering Cancer CenterUConn HealthActive, not recruitingAdvanced CancerUnited States
-
Goethe UniversityKatholische Universität Eichstätt Ingolstadt; Freie Universität BerlinCompleted
-
Centre Henri BecquerelCompleted
-
Fondazione Italiana Linfomi - ETSNot yet recruitingDiffuse Large B Cell Lymphoma | Follicular Lymphoma Grade 3BItaly
-
Yuanjiao YanCompletedDiabetes | Senile Dementia, Alzheimer TypeChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Kaleido BiosciencesCompletedMild-to-Moderate COVID-19United States
-
Kaleido BiosciencesCompletedMild-to-moderate COVID-19United States
-
Lepu Biopharma Co., Ltd.Not yet recruiting
-
VA Office of Research and DevelopmentCompletedLung CancerUnited States